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ABSTRACT
Acute intake of the wheat bran extract Arabinoxylan-Oligosaccharide (AXOS) modulates the gut
microbiota, improves stool characteristics and postprandial glycemia in healthy humans. Yet, little
is known on how long-term AXOS intake influences gastrointestinal (GI) functioning, gut micro-
biota, and metabolic health. In this randomized, placebo-controlled, double-blind study, we
evaluated the effects of AXOS intake on GI function and metabolic health in adults with slow GI
transit without constipation. Forty-eight normoglycemic adults were included with whole-gut
transit time (WGTT) of >35 h receiving either 15 g/day AXOS or placebo (maltodextrin) for 12-wks.
The primary outcome was WGTT, and secondary outcomes included stool parameters, gut
permeability, short-chain fatty acids (SCFA), microbiota composition, energy expenditure, sub-
strate oxidation, glucose, insulin, lipids, gut hormones, and adipose tissue (AT) function. WGTT
was unchanged, but stool consistency softened after AXOS. 12-wks of AXOS intake significantly
changed the microbiota by increasing Bifidobacterium and decreasing microbial alpha-diversity.
With a good classification accuracy, overall microbiota composition classified responders with
decreased WGTT after AXOS. The incretin hormone Glucagon-like protein 1 was reduced after
AXOS compared to placebo. Energy expenditure, plasma metabolites, AT parameters, SCFA, and
gut permeability were unchanged. In conclusion, intake of wheat bran extract increases fecal
Bifidobacterium and softens stool consistency without major effects on energy metabolism in
healthy humans with a slow GI transit. We show that overall gut microbiota classified responders
with decreased WGTT after AXOS highlighting that GI transit and change thereof were associated
with gut microbiota independent of Bifidobacterium. NCT02491125
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Introduction
Dietary fibers are well known for their beneficial
health effects, but the exact underlying mechan-
isms are not fully understood. Specific dietary
fibers termed prebiotics are fermented by the gut
microbiota thereby altering the microbial compo-
sition and activity thus conferring a beneficial phy-
siologic effect on the host.1 Prebiotic intake can
reduce postprandial glycemic and insulinemic
excursions, increase satiety, improve the gut
barrier function and decrease inflammatory
markers.2 Short-chain fatty acids (SCFA) produced
upon microbial prebiotic fermentation are sug-
gested to mediate metabolic effects by modulating
gut peptide release (peptide YY (PYY) and gluca-
gon-like peptide-1 (GLP-1)), gut permeability, ske-
letal muscle, liver, and adipose tissue (AT)
function.3,4 Combined data in systematic reviews
regarding prebiotic interventions to improve func-
tional gastrointestinal disorders5 or metabolic
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markers in type 2 diabetes6 and obesity7 are pro-
mising. Yet mostly due to study heterogeneity,
regarding, for example, prebiotic fiber types, par-
ticipant heterogeneity, duration of intervention as
well as clinical endpoints, these reviews generally
report a low to moderate level of evidence for the
efficacy of prebiotics in the given disease context.
The gastrointestinal (GI) transit is an important
for healthy gut functioning as well as in human
energy metabolism. Upper intestinal transit is
tightly involved in satiety signaling, the incretin
response and postprandial glycemia, while lower
intestinal transit determines nutrient availability,
wash-out rate, and water availability, thereby shap-
ing the ecologic niche of the gut microbiota.8-14
Conventionally, insoluble fibers are known to
accelerate GI transit time possibly by increased
stool bulk potentially caused by mechanical irrita-
tion and stimulation of mucus and water secretion
in the large intestine.15 However, prebiotic mod-
ulation of gut microbiota and microbial metabolite
production (e.g. SCFA, H2) may also affect GI
transit.8 Some prebiotics (namely fructans and
galacto-oligosaccharides) may increase stool fre-
quency and soften stool consistency more effec-
tively in constipated compared to non-constipated
participants supporting evidence that dietary fiber
intake more effectively accelerates gastrointestinal
transit in humans with initially longer transit.16-18
Short-term human studies with the novel prebio-
tic arabinoxylan-oligosaccharides (AXOS) derived
from wheat bran have been reported to increased
Bifidobacterium abundance and improve postpran-
dial glycemia.19-23 Further, AXOS intervention sof-
tened stool consistency and increased stool
frequency in some,23-25 but not all short-term
human interventions.20,22 Yet it is unknown how
AXOS affects gastrointestinal transit and metabolic
health in the long-term. We hypothesized that 12-
week AXOS intake improves whole-gut transit time
(WGTT, primary outcome) in healthy participants
with a slow GI transit but without constipation. This
selection was based on the assumption that partici-
pants who are non-constipated, yet not satisfied with
their bowel habits (i.e. with slowGI transit) would be
the likely population to use dietary fiber supplements
such as AXOS to alleviate GI transit. Secondary out-
comes were changes in gut microbiota composition,
gastric emptying, oro-cecal transit, gut permeability,
fecal and plasma SCFA, energy and substrate meta-
bolism, glycemic and insulinemic responses, gut hor-
mones, systemic and local inflammatory markers as
well as AT functioning after 12-week of AXOS intake
compared to placebo.
Participants and methods
Study participants
Forty-eight healthy Caucasian men and women aged
20–55 years, with a body mass index of 20–30 kg/m2
were recruited between August 2015 and
December 2016 from the general population in the
vicinity of Maastricht, the Netherlands. Initial recruit-
ment was based on a defecation frequency of ≤4 per
week. Participants with WGTT >35 h determined by
radio-opaque marker method were included.
Normoglycemia was determined by an oral glucose
tolerance test according to the diagnostic criteria of the
American Diabetes Association, 2010.26 During
a medical screening, eligibility was assessed including
anthropometrics and medical history. Exclusion cri-
teria were: Two or more symptoms of constipation
according to ROME III criteria27 to rule out any con-
founding effects of underlying pathologies (e.g. defe-
cation disorders, outlet obstruction), other unknown
pathologies or inevitable medication use. Further
exclusion criteria were the diagnosis of diabetes,
prior abdominal surgery, cardiovascular or gastroin-
testinal diseases, life expectancy shorter than 5 years,
the use of antibiotics, laxatives, prebiotics or probiotics
3 months prior to the study or during study participa-
tion. Participants did not use β-blockers, lipid- or
glucose-lowering medication or corticosteroids.
Study design
This study was a double-blind, randomized placebo-
controlled parallel trial approved by the Medical
Ethical Committee of Maastricht University Medical
Center+ (METC 15-3-005) and was conducted
according to the ethical standards of the Helsinki
Declaration and in accordance with the Medical
Research Involving Human Subjects Act (WMO).
All patients provided verbal and written informed
consent. Using block randomization, an independent
researcher randomly allocated participants to AXOS
or placebo group with stratification for age and sex.
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After inclusion, two clinical investigation days (CID)
before and directly after the 12-week intervention
were performed to asses primary and secondary out-
comes (Supplemental Figure 1). Participants were
asked to ingest 5 g of AXOS powder (Cargill,
Minnetonka, Minnesota, U.S.) or 5 g maltodextrin
(C-PharmDry™, Cargill) three times per day with
their regular meals for 12 weeks. AXOS preparations
consisted of 71%of drymatter (DM)AXOS (degree of
polymerization of the main AXOS fraction varies
between 2 and 15 (average degree of polymerization:
3–8)), 10–14% DM β-glucan and 1–3% DM ferulic
acid. AXOS and maltodextrin were provided as off-
white powder, prepackaged in identical opaque
sachets to be dissolved in tap water insuring the dou-
ble-blind study design. Compliance was checked by
the number of returned empty sachets. Participants
were instructed to maintain habitual food intake and
physical activity pattern throughout the study mon-
itored by the short questionnaire to asses health-
enhancing physical activity28 and a weighed 3-day
food record before and during the last week of the
intervention (see supplementary methods). To asses
gastrointestinal complaints, participants documented
a 7-day gastrointestinal symptoms questionnaire
including stool frequency and consistency using the
Bristol stool scale (BSS)29 the week before and during
the last week of intervention. Quality of life was
assessed via the 36-Item short form healthy survey of
quality of life30 before and after the intervention (see
supplementarymethods). Two days prior to the CIDs,
participants were asked to refrain from intense physi-
cal activity, alcohol and natural 13C-enriched products
(e.g. pineapple, corn, and cane sugar).
Clinical investigation day 1
Whole-gut transit time
Prior to clinical investigation day (CID) 1, on 6 con-
secutive days participants ingested 10 radio-opaque
(Colonic Transit, P. & A. Mauch, Münchenstein,
Switzerland) markers in the morning. On CID1, par-
ticipants came fasted to the university and a single
abdominal X-ray was taken 24 h after the last marker
ingestion. Based on the number of markers visible on
the abdominal X-ray, WGTT was calculated accord-
ing to Metcalf et al.31
Gut permeability
Thereafter, participants ingested a multi-saccharide
mix dissolved in 150 ml tap water containing 1
g sucrose (Van Gilse, Dinteloord, The Netherlands),
1 g lactulose (Centrafarm, Etten-Leur, The Nether
lands), 1 g sucralose (Brenntag, Sittard, The Nether
lands), 1 g erythritol (Nowfoods, Bloomingdale, U.S.),
and 0.5 g of l-rhamnose (Danisco Sweeteners,
Copenhagen, Denmark). Urine was collected in frac-
tions to determine sucrose concentrations after 0–5
h for gastro-duodenal permeability, lactulose/rham-
nose ratio after 0–5 h for small intestinal permeability,
and the sucralose/erythritol ratio after 5–24 h for colo-
nic permeability as described previously.32 Isocratic
ion-exchange HPLC (Model PU-1980 pump) with
mass spectrometry (Model LTQ XL, Thermo Fisher
Scientific, Landsmeer, The Netherlands) was used to
determine urinary sugar concentrations.
Clinical investigation day 2
Adipose tissue biopsy
After an overnight fast, abdominal subcutaneous
adipose tissue (AT) needle biopsies were collected
under local anesthesia lateral from the umbilicus
in a subgroup of participants (AXOS n = 15,
placebo n = 15). Biopsy specimens were fixed
overnight in 4% paraformaldehyde and embedded
in paraffin. Histological sections were cut to 8 μm
slices, mounted on microscope glass slides and
dried overnight at 37C. After hematoxylin eosin
staining, digital imaging was performed using
Leica DFC320 digital camera (Leica, Rijswijk,
Netherlands) at × 20 magnification (Leica
DM3000 microscope; Leica). Computerized mor-
phometric measurements of individual adipocytes
were performed as previously described.33 For AT
mRNA expression, total RNA was extracted using
TRIzol (Invitrogen, Breda, The Netherlands) for
cDNA synthesis and real-time qPCR (iCycler, Bio-
Rad, Veenendaal, NL, U.S.; primer sequences
Supplemental Table 6). Results were normalized
to 18S rRNA and expressed relative to baseline
expression according to ΔΔCt method.
Breakfast meal test and indirect calorimetry
After the AT biopsy, venous blood samples were
taken at t = 0, 30, 60, 90, 120, 180, 240 and 300 min
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after ingestion of a solid test meal consisting of two
slices of white bread, a fried egg and 250 ml of
chocolate milk (27 E% fat, 52 E% carbohydrate, 19
E% protein, 412 kcal). During fasting and postpran-
dial, visual analogue scales of feelings of hunger,
satiety, fullness, and desire to eat were assessed.
Substrate oxidation and energy expenditure was
measured by determining CO2 production and O2
consumption via an open-circuit-ventilated hood
system (Omnical, Maastricht University, The
Netherlands) for 30 min during fasted conditions
and in 15 min intervals during the 5 h postprandial
state. Calculations of energy expenditure and the rate
of fat and carbohydrate oxidation were calculated
assuming 15% protein oxidation using the equations
of Weir34 and Frayn.35
Upper gastrointestinal transit
Gastric emptying (GE) was measured using
13C-octanoic acid (100 mg, Campro Scientific bv,
Veenendaal, The Netherlands) mixed into the
standardized breakfast meal consumed at t = 0.
Breath samples were collected at fasting and dur-
ing the 5 h postprandial state, and analyzed using
non-dispersive infrared spectrometry (IRIS,
Wagner, Bremen, Germany).36 Two fasting breath
samples were obtained to measure baseline
13C-concentration to calculate delta over baseline
and percentage of the dose 13C recovered (%/h)
from the subsequent time points. Gastric emptying
describing the time point at which 50% of the
gastric content is excreted (T1/2), and the time
point of maximal excretion rate (Tlag) were calcu-
lated according to Ghoos et al.37 Oro-cecal transit
time (OCTT) was determined using the inulin
hydrogen (H2) breath test.
38 Participants ingested
5 g of Inulin (Cargill) dissolved in 150 ml tap
water with the breakfast meal at t = 0. A hand-
held device (Gastrolyzer, Bedfont Scientific, Kent,
UK) was used to measure breath H2 (in ppm) as
an indicator of at fasting and every 15 min during
the 5 h postprandial state. OCTT was estimated
from three consecutive measurements at least 10
ppm above baseline at fasting.
Biochemical blood analyses
Blood was collected in pre-chilled tubes and cen-
trifuged at 3 000 x g at 4°C and plasma was snap-
frozen in liquid nitrogen and stored at -80°C until
analyses. EDTA tubes (Becton Dickinson, Eysins,
Switzerland) were used for SCFA, insulin, glucose,
free fatty acids (FFA), triacylglycerol (TAG), free
glycerol, lipopolysaccharide-binding protein
(LBP), Tumor necrosis factor (TNF) α,
Interleukin (IL) 6, IL-1β and IL-8 analyses. For
GLP-1 and PYY, 20 μL of dipeptidyl peptidase-
IV inhibitor (Merck, Darmstadt, Germany) was
added into an EDTA or Aprotinin tube (Becton
Dickinson), respectively. Glucose, FFA, and TAG
were determined with enzymatic assays (Cobas
Fara auto-analyzer, Roche, Basel, Switzerland).
Free glycerol was measured after precipitation
using an enzymatic assay (Enzytee™ Glycerol,
Roche) and analyzed with the Cobas Fara auto-
analyzer. Insulin and PYY concentrations were
determined using radio-immunoassay (RIA) kits
(Human PYY (3–36) Specific RIA, Merck). Total
GLP-1 was measured with RIA as previously
described.39 LBP was measured using
a noncommercial enzyme-linked immunosorbent
assay (ELISA) as previously described.40 IL-1β, IL-
6, IL-8, and TNF-α were determined with an
ELISA kit (Human ProInflammatory IL 4-Plex
Ultra-Sensitive Kit, Meso Scale Diagnostics,
Rockville, U.S.). Plasma SCFA were determined
using liquid chromatography-mass spectrometry.41
Fecal sample collection and analyses
Feces wet weight was recorded by the participants
for four consecutive days at home before CID1.
From the first weighted stool, fractions of feces
were collected in tubes for further analysis. Feces
tubes were stored at -20°C in the participants’
freezers and transported using ice packs and
immediately stored at -80°C on arrival at the
University for CID 1. Fecal calprotectin was deter-
mined using an ELISA kit (BÜHLMANN fCAL®,
Basel, Switzerland). Fecal SCFA, branched-chain
fatty acids (BCFA), succinate and lactate were
measured using ion exchange chromatography
with conductivity detection and normalized to
dry weight (Brightlabs, Venlo, The Netherlands).
Stool moisture, i.e., water percentage of a stool
sample (approx. 3 grams) was calculated based
on the ratio of the weight loss of a fecal sample
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after 24 h of dry lyophilization to the weight of the
fecal sample before.
Gut microbiota composition
Microbial DNA was extracted from fecal samples to
perform 16S rRNA gene amplicon sequencing with
Illumina Hiseq2500. DNA was isolated from 0.25
g feces with repeated bead beating followed by auto-
mated isolation and purification using a Maxwel 16
Tissue LEV Total RNA Purification Kit (Promega,
Madison, U.S.). DNA was eluted in 50ul of nuclease-
free water and quantified by Nanodrop
(ThermoScientific). The V4 region of the 16S rRNA
gene was amplified with the double barcoded primer
pair 515F (5’-GTGCCAGCMGCCGCGGTAA) –
806R (5’-GGACTACHVGGGTWTCTAAT) as pre-
viously described.42,43 Each sample was amplified in
triplicate using Phusion hot start II high fidelity poly-
merase (Thermo Scientific). Forty μl PCR reactions
contained 28.4 μL nucleotide-free water (Promega,
Madison, USA), 0.4 μL of 2 U/μl polymerase, 8 μL of
5× Phusion Green HF Buffer, 0.8 μl of 10 μM stock
solutions of each of the barcoded forward (515F) and
reverse (806R) primers, 0.8 μL 10mM dNTPs
(Promega) and 0.8 μL template DNA. Cycling condi-
tion were as follows; Reactions were held at 98°C for
30 s and amplification proceeding for 25 cycles at 98°C
for 10 s, 50°C for 10 s, 72°C for 10 s and a final
extension of 7 min at 72°C. PCR products were
checked for correct size on a 1% agarose gel and
subsequently combined and purified with the
CleanPCR kit (CleanNA, Alphen aan den Rijn, The
Netherlands). Purified PCR products were quantified
with Qubit using the dsDNA BR Assay Kit
(Invitrogen, Caliornia, USA) and a composite sample
for sequencing was created by combining equimolar
amounts of amplicons (200 ng) from the individual
samples. The resulting libraries were sent to GATC
Biotech AG for 2X150nt sequencing on an Illumina
Hiseq2000 instrument. Sequencing yielded 387 497 ±
SD 164 372 reads per sample and sequence analysis
was performed in NG-Tax using default settings.42
Paired-end libraries were demultiplexed using read
pairs with perfectly matching barcodes. Amplicon
sequence variants (ASV) were picked as follows:
sequences were ordered by abundance per sample
and reads were considered valid when their cumula-
tive abundance was ≤0.1%. Taxonomy was assigned
using the SILVA reference database version128.44
ASVs are defined as individual sequence variants
rather than a cluster of sequence variants with
a shared similarity above a specified threshold.
Statistics
To measure clinically relevant differences in
WGTT of 30%, a power of 80% (β) and assum-
ing an alpha of 0.05 (α), 22 participants per
group were required. Estimating a 20% dropout
rate, total recruitment included n = 48 partici-
pants. Data were tested for normality using
a Shapiro Wilk test and were log-transformed
in case of a non-parametric distribution and in
case of ordinal data, a Wilcoxon signed rank
tests was performed. Baseline differences were
analyzed using unpaired Student’s t-tests.
Primary and secondary outcomes were com-
pared using a 2-factor repeated measures ana-
lysis of variance with time (pre, post) and
intervention (AXOS, placebo). In case of
a significant time*intervention effect, a post
hoc analysis was conducted with Bonferroni
correction within both groups. P-values <0.05
were considered significant. Statistical analyses
were performed using SPSS 22.0 (IBM, Armok,
U.S.). For the gut microbiota, analyses were
performed in R version 3.4 (R Core Team,
2017). Distance-based redundancy analysis
with weighted Unifrac was performed to calcu-
late the multivariate intervention effect.45,46
Principal response curve (PRC) analysis was
used to summarize differences in the micro-
biota composition between interventions over
time.47 Alpha diversity metrics were calculated
using vegan package.48 To classify responder
status based on gut microbiota, we used ran-
dom forests (RF) based on ASVs. Three out-
liers outside an overall 95% confidence interval
on a weighted Unifrac based PCoA analysis
were discarded. We evaluated the model using
cross-validation as implemented in caret.49 We
randomly selected 75% of the samples to serve
as the training set and consequently evaluated
classification accuracy using the hold out set
with 500 repetitions. The AUC was calculated
with the cross-validation error using the pROC
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package with 10 000 bootstraps for confidence
intervals.50
Results
Participant characteristics
Forty-eight participants were included and com-
pleted the study (Table 1, Supplemental Figure 2).
No serious adverse events or gastrointestinal com-
plaints (Supplemental Table 1) were reported, and
compliance was checked by returned emptied
sachets (236 ± 12 of 252 empty sachets were returned
[93.7%]). There were no differences in BMI, body
composition, dietary intake, physical activity and
quality of life between groups before or after the
intervention (Supplemental Table 2–4).
Softer stool consistency but no changes in whole
gut transit after AXOS
No significant changes inWGTT, gastric emptying or
OCTT were observed after AXOS intervention com-
pared to placebo (Table 2). Independent of interven-
tion or time, gastric emptying of the solid meal was
uniformly overestimated, a known limitation of indir-
ect breath test fitting.51 Yet, the unfitted percentage of
13C recovery was unchanged after AXOS intervention
compared to placebo (Supplemental Figure 3). Stool
frequency, stool weight, stoolmoisture, and fastingH2
remained unchanged, however, BSS scores increased
from harder stool type 1–2 toward softer stool types
3–4 after AXOS intervention (Table 2, Supplemental
Figure 4). WGTT and BSS were not correlated,
neither at baseline nor when comparing changes
after the intervention (Supplemental Figure 5).
There were no changes in BSS scores after placebo,
yet we observed that there was a non-significant
increase of stool type 6 scoring (watery stool) after
placebo intake. In general, we observed very irregular
patters of BSC types within 1 week, for example,
having stool forms of type 2 and type 6 within 1
week. Thus, in the placebo group, this irregular pat-
tern was maintained or even exacerbated, while we
observed a tendency toward “normal” stool types (i.e.,
3 and 4) after the AXOS intervention. Participants did
not report the use of laxatives during the study as
monitored via GI questionnaires.
AXOS intervention modulates gut microbiota
AXOS intervention significantly reduced alpha diver-
sity (P< .001) and changed the microbiota composi-
tion (P= .05) compared to placebo (Figure 1(a)) after
adjustment for age and sex. Furthermore, 15.1% of the
variation in microbiota composition was explained by
time (P < 1*10−5), and 4.4% (P= .05) by the time*-
intervention effect. Gut microbiota changes after
AXOS intervention were mainly related to increased
BifidobacteriumASVs and, to a lesser extent, increased
Akkermansia, Prevotellaceae NK3831 group,
Lactobacillus and decrease of Blautia, Eubacterium
Hallii group, Coriabacteriaceau UCG-003, and Dorea
ASVs (Figure 1(b)). Nonetheless, the overall microbial
responses to AXOS showed distinct individual pat-
terns as exemplified by the Blautia and Dorea ASVs
(Figure 1(c)).
Fecal and plasma SCFA
Fecal SCFA, BCFA, succinate or lactate were
unchanged after AXOS intervention compared to
placebo (Figure 2(a–c), Supplemental Figure 6).
Plasma acetate and butyrate decreased over time
both after AXOS and placebo intervention with no
differences between groups (Figure 2(d–f)).
Gut permeability and inflammation
Gut permeability, plasma LBP, fecal calprotectin,
plasma IL-6, IL-8, TNF-α, and IL-1β were unchanged
Table 1. Baseline characteristics of the study participants.
Variables
AXOS (n =
24)
Placebo (n =
24) P
Sex, male/female 6/18 6/18
Age, y 36.1 ± 12.9 35.7 ± 11.0 .905
Weight, kg 72.7 ± 12 72 .5 ± 11.7 .912
Body mass index, kg/m2 24.7 ± 3.1 24.2 ± 2.3 .532
Body fat, % 25.4 ± 7.2 25.5 ± 8.4 .861
Fat mass, kg 18.4 ± 5.7 19.2 ± 7.6 .952
Systolic blood pressure, mmHg 116 ± 9 115 ± 11 .532
Diastolic blood pressure,
mmHg
79 ± 5 76 ± 8 .125
Fasting glucose, mmol/L 4.8 ± 0.3 5.0 ± 0.3 .067
OGTT 2h plasma glucose,
mmol/L
4.7 ± 1.2 4.9 ± 1.1 .503
Whole-gut transit time, h 70.8 ± 26 80.2 ± 21 .084
Values are given as means ± SD. Group differences were assessed using
independent Student’s t-test. OGTT oral glucose tolerance test, AXOS
Arabinoxylan-Oligosaccharides
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Table 2. Gastrointestinal transit and stool parameters before and after AXOS and Placebo intervention.
Variable AXOS (n = 24) Placebo (n = 24) P
Whole-gut transit, h Pre 70.8 ± 26 80.2 ± 21 .266
Post 71.8 ± 31 66.1 ± 30
Oro-cecal transit, min Pre 212 ± 95 235 ± 86 .725
Post 235 ± 22 229 ± 18
GE half time (Thalf), min Pre 191 ± 55 182 ± 49 .801
Post 207 ± 38 195 ± 32
GE lag time (Tlag), min Pre 130 ± 43 128 ± 38 .235
Post 150 ± 29 144 ± 25
Fasting H2, ppm Pre 10.2 ± 6 9.9 ± 7 .992
Post 12.2 ± 2.1 9.9 ± 8
Stool frequency, stools/week Pre 4.1 ± 2.8 4.0 ± 1.2 .880
Post 5.0 ± 3.4 5.0 ± 1.7
Stool wet weight, g/day Pre 180 ± 22 196 ± 20 .735
Post 145 ± 15 165 ± 15
Stool moisture, % Pre 69.6 ± 7.7 65.3 ± 8.7 .766
Post 66.9 ± 11.2 61.1 ± 10.8
BSS, score/day Pre 3.0 [2.1–3.4] 3.3 [2.8–4.0] AXOS *P= .018
Post 3.5 [2.8–4.3] 3.3 [2.7–4.0] Placebo *P= .676
Data are given in mean ± SD and for BSS in median ± IQR [25–75th]. Data (except BSS) were analyzed using 2-way repeated
measure ANOVA with time (pre/post) and intervention as covariates. P-value represents time*intervention interaction. BSS scores
were compared pre/post within groups with Wilcoxon signed-rank test represented by *P-value. BSS scores significantly
increased after AXOS but not after placebo intervention compared to baseline. GE gastric emptying, AXOS Arabinoxylan-
Oligosaccharides, BSS Bristol stool scale
a b
c
Figure 1. AXOS induces changes in gut microbiota. (a) Inverse Simpson index for alpha-diversity is reduced after AXOS
intake. (b) Principal Response Curve summarizing the multivariate response of AXOS intervention versus Placebo over time
(P = .05). ASVs with large deviations between AXOS and Placebo have high weights while taxa equally present in AXOS and
Placebo have zero weight. ASVs with the highest weight plotted vertically on the right axis are the main drivers of the
differences between interventions. ASVs that have a negative weight on the response curve follow the observed AXOS
curve, whereas those with positive weights follow the opposite pattern. (c) Individual intervention responses of important
ASVs. Individual changes depict the AXOS group (n = 21) and placebo (n = 17) before and after the intervention. ASV
Amplicon sequence variant, AXOS Arabinoxylan-Oligosaccharides.
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after AXOS intervention compared to placebo (Figure
2(g–i), Supplemental Table 5).
Energy metabolism, plasma metabolites and
adipose tissue function
Postprandial fat oxidation tended to increase after
AXOS intervention (iAUC0-5h, ANOVA P = .008,
post-hoc AXOS P = .073, placebo P = .089, Figure 3
(a,b)). AXOS intervention did not affect energy
expenditure, respiratory quotient and carbohydrate
oxidation (Figure 3(c–f)), yet AXOS intervention
decreased early postprandial GLP-1 AUC 0–90min/
min concentrations after a standardized breakfast
meal as compared to placebo (ANOVA P = .043,
post-hoc AXOS P= .033, placebo P = .972. Figure 3
(g,h)) while PYY was unchanged after intervention
(Figure 3(i)). Glucose, insulin, FFA, TAG, glycerol
and appetite, hunger, satiety, and fullness ratings
were not affected by AXOS intervention compared
to placebo (Table 3, Supplemental Figure 7). AXOS
intervention had no effect on adipocyte size and AT
a d g
b e h
c f i
Figure 2. Short-chain fatty acid concentrations and gut permeability before and after AXOS (n = 24) and placebo intervention (n = 24). Data
are given as means ± SEM. Data were analyzed using 2-way repeated measure ANOVA with time (pre/post) and intervention as covariates.
There are no differences between fecal (a) acetate (b) propionate, (c) butyrate or fasting and postprandial plasma (d) acetate, (e) propionate,
(f) butyrate between groups as a result of intervention (time*intervention, ns). Urinary sugar excretions and ratios were compared with
Wilcoxon signed-rank test pre vs. post within groups. There were no differences in urinary excretion rates of (g) 0–5 h sucrose (gastro-
duodenal permeability) (h) 0–5 h Lactulose:Rhamnose ratio (small intestinal permeability) (i) 5–24 h Sucralose:Erytrithol ratio (colonic
permeability). AXOS Arabinoxylan-Oligosaccharides, PLA placebo.
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mRNA expression of lipolytic enzymes (adipose tis-
sue triglyceride lipase (ATGL), hormone-sensitive
lipase (HSL), comparative gene identification 58
(CGI-58), lipid-droplet-associated protein (PLIN-1,
Supplemental Figure 8)).
Microbiota composition relates to decreased
WGTT after AXOS
To identify responders and non-responders, we
defined responders as a ≥ 10% decrease in WGTT
and non-responders as unchanged/increase inWGTT
after AXOS intervention. We used Random Forests
analysis to determine gut microbiota patterns
characteristic for responders or non-responders after
AXOS intervention. With a good classification accu-
racy (Area Under the Receiver Operating
Characteristics curve, AUROC of 0.80, Figure 4(a)),
we observed that overall microbiota composition clas-
sified decreased WGTT (responders) compared to
unchanged/increased WGTT (non-responders) after
AXOS intervention. ASVs important for this classifi-
cation were mainly ASV 22851231 from the genus
Senegalimassilia, family Coriobacteriaceae and an
unclassified ASV 22851212 from the family
Lachnospiraceae (Figure 4(b)), which showed higher
abundances in responders compared to non-
responders (Figure 4(c)).
a b c
ed f
h ig
Figure 3. Energy expenditure, substrate metabolism, GLP-1 and PYY before and after AXOS (n = 24) and Placebo (n = 24)
intervention. Data are mean ± SEM and analyzed using 2-way repeated measure ANOVA with time (pre/post) and intervention as
covariates. (a,b) Postprandial fat oxidation iAUC0-5h tended to increase after AXOS intervention (time*intervention P< .01, post-hoc
AXOS P = .073, placebo P = .089). (c) Energy expenditure, (d) CHO oxidation, (e) CHO oxidation iAUC and (f) RQ were unchanged
between groups after intervention. (g,h) Postprandial GLP-1 AUC0-90min decreased after AXOS intervention compared to placebo
(time*intervention P = .043, post hoc AXOS P= .33, placebo P= .972). (i) PPY was not affected by the intervention. AXOS
Arabinoxylan-Oligosaccharides, CHO carbohydrate, GLP-1 glucagon-like peptide-1, PYY peptide YY, iAUC incremental area under
the curve, EE energy expenditure, RQ respiratory quotient, * P < .05.
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Discussion
This is the first study investigating the effects of 12-
week AXOS intake on combined measures of gastro-
intestinal functioning and metabolic health in healthy
participants with a slowGI transit. AXOS intervention
did not affect whole-gut transit (WGTT) but signifi-
cantly increased fecal Bifidobacterium, decreased
microbial diversity and softened stool consistency
compared to placebo. Further, responder analysis
showed that overall microbiota composition accu-
rately classified responders with decreased WGTT as
well as non-responders with unchanged/increased
WGTT after AXOS intervention. Postprandial fat oxi-
dation tended to increase and early postprandial GLP-
1 significantly decreased after AXOS while upper
intestinal transit, stool frequency, SCFA, gut perme-
ability, inflammatory markers as well as glucose, insu-
lin and lipid metabolism and adipose tissue
functioning were not affected by AXOS.
Bifidobacterium spp. has been shown to accel-
erate gastrointestinal transit in healthy humans
when administered as probiotics.52,53 In this
study, the AXOS-mediated bifidogenic effect did
not translate into changes in quantitative measures
of gastrointestinal transit but was accompanied by
softer stool consistency consistent with previous
studies.23-25 WGTT and BSS were not correlated
in this study which may explain the different out-
comes between the rather subjective BSS and the
quantitative radio-opaque marker method. After
the AXOS intervention, we observed an average
BSS change of 0.5, which may be debatable with
regards to its clinical relevance. According to FDA
guidelines, change in a BSS of more than 1 is
considered clinically relevant in inflammatory
bowel disease diarrhea and constipation
subtypes.54 However, to date, there is no specific
suggestion for clinically relevant changes in BSS in
the healthy population. Thus, an increase of 0.5 in
the Bristol stool score may be regarded as
Table 3. Circulating metabolites and insulin before and after
AXOS and Placebo intervention.
Variables AXOS (n = 24)
Placebo (n =
24) P
Fasting
Glucose, mmol/L Pre 4.93 ± 0.06 4.95 ± 0.05 .586
Post 4.94 ± 0.05 4.98 ± 0.05
TAG, μmol/L Pre 813 ± 56 896 ± 103 .534
Post 706 ± 59 860 ± 119
FFA, μmol/L Pre 547 ± 37 536 ± 41 .961
Post 567 ± 50 553 ± 38
Glycerol, μmol/L Pre 81.5 ± 8 84.4 ± 7 .410
Post 91.0 ± 11 83.7 ± 7
Insulin, mU/L Pre 8.4 ± 0.6 8.8 ± 0.9 .821
Post 7.8 ± 0.6 7.9 ± 0.5
Postprandial (0–5 h) plasma metabolites
Glucose, iAUC/min Pre 0.11 ± 0.09 0.32 ± 0.01 .576
Post 0.14 ± 0.09 0.27 ± 0.09
TAG, iAUC/min Pre 117 ± 24 179 ± 22 .183
Post 175 ± 39 177 ± 21
FFA, iAUC/min Pre −268 ± 31 −243 ± 33 .620
Post −302 ± 42 − 253 ± 24
Glycerol, iAUC/min Pre −15 ± 5 −22 ± 6 .171
Post −25 ± 9 −17 ± 5
Insulin, iAUC 0-5 h/min Pre 23.1 ± 2.5 20.4 ± 1.9 .316
Post 22.5 ± 2.6 22.1 ± 2.1
Data are mean ± SEM and analyzed using 2-way repeated measure
ANOVA with time (pre/post) and intervention as covariates. P-value
represent time*intervention interaction. There were no differences
between groups as a result of intervention. TAG Triacylglycerol, FFA
free fatty acids, iAUC incremental area under the curve, AXOS
Arabinoxylan-Oligosaccharides
a b c
Figure 4. Identification of microbial ASVs as markers for responders with decreased WGTT after AXOS intervention by random forests
models with 500-fold cross-validation. (a) The cross-validation error-based AUC was 79.9% with 10 000 bootstraps for a 95%
confidence interval (65.8–94.0%). (b) The top 10 microbial ASVs that were important for the classification of responders with
decreased WGTT. On the x-axis, MeanDecreaseAccuracy displays the decrease of model accuracy if the predictor ASV would be
removed. (c)The abundance of the top 10 microbial groups in responders and non-responders after AXOS intervention. FDR adjusted
P-values are given of a Wilcoxon signed-rank test between responders and non-responders. WGTT whole-gut transit time. AUC, area
under the curve, AXOS, Arabinoxylan-Oligosaccharides, FDR false discovery rate.
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normalization of the stool consistency while the
clinical relevance in a healthy population needs yet
to be validated.
Despite being of lower avDP than other
Arabinoxylans or other well-known prebiotics,
AXOS with avDP <10 have been shown to induce
a bifidogenic effect in animals and humans.20,22,55,56
This indicates that AXOS indeed reaches the colon
inducing changes in the gut microbiota composition,
which most likely occurs mainly in the proximal
colon. Possible AXOS-mediated mechanisms contri-
buting to softer stools may be an increased fecal bac-
terial biomass, increased water binding capacity or
stimulation of host mucus production.57 Further,
AXOS intake decreased microbial alpha diversity,
while high microbial diversity is commonly regarded
as a biomarker for a stable, healthy gut ecosystem.
However, hard stool has been associated with
increased alpha diversity reflecting a diversification
as an adaption to a changing ecosystem during long
colonic passage (i.e., depletion of nutrients, switch
from microbial saccharolytic to proteolytic fermenta-
tion, microbial competition, decreased water
availability).10 Thus, microbial diversity should be
interpreted within the physiological context: in parti-
cipants with slow GI transit, softer stool after AXOS
intervention may have contributed to the observed
reduced alpha diversity which may reflect the AXOS
induced shifts in themicrobial and colonic ecosystem.
Further, reduced alpha diversity may have been
a result of the selective stimulation of
Bifidobacterium growth, and not necessarily represent
a reduced microbiota stability. Despite observing no
changes in WGTT after AXOS intake compared to
placebo, the within-participants variability was
remarkable in response to the AXOS intervention.
Thus, we further explored the association between
responders with a decreased WGTT and non-
responders with an unchanged/increased WGTT
after AXOS intervention and the gut microbiota com-
position. We observed that the overall gut microbiota
composition could accurately classify responder status
indicating that the relationship between gut micro-
biota and GI transit is potentially bidirectional.
Responsible for this classification were mainly
Senegalimassilia ASV (family Coriobacteriaceae, phy-
lum Actinobacteria), and an unclassified ASV from
the family Lachnospiraceae (phylum Firmicutes)
which were significantly more abundant in the
responders compared to non-responders.
Unfortunately, not much is known about
Senegalimassilia and the ASV from the family of
Lachnospiraceae, which is among the most abundant
in the human gut, making it difficult to speculate on
their mode of action. Other predictors were common
members of the gutmicrobiota from different families
and phyla. Hence, changes in GI transit may be
mediated by a microbial network comprising species
of these families rather than the selective stimulation
of Bifidobacterium.
Colonic SCFA may affect gastrointestinal moti-
lity via stimulation of enterochromaffin cells
amongst other mechanisms.58 Despite the increase
of acetate-producing Bifidobacterium, plasma and
fecal SCFA concentrations were not affected by
AXOS intervention. Of note, we observed a time-
dependent decrease in plasma acetate and butyrate
in both groups reflecting a high temporal variability
in SCFA metabolism. Circulating acetate and buty-
rate have several sources: 1) direct exogenous inges-
tion via food sources, 2) indirect exogenous
production by colonic bacterial fermentation of
non-digested food components, and 3) endogenous
production from protein, lipid, and carbohydrate
catabolism in mainly the liver.4 Plasma SCFA con-
centrations are thus the net result of SCFA produc-
tion, absorption and splanchnic extraction/hepatic
metabolism, and are therefore difficult to interpret.
Since rate of appearance from endogenous or exo-
genous sources can only be acquired by using stable
isotope tracer techniques, we cannot provide this
information for the present study.
Early postprandial GLP-1 was reduced after
AXOS intervention, whilst PYY, insulin, glucose
concentrations as well as ratings of hunger and
satiety were unchanged. Acute AXOS studies
reported inconsistent effects on GLP-1,19,59 how-
ever, arabinose derived from arabinoxylan fermen-
tation has been proposed to be rapidly fermented
in the small intestine as observed by an early
postprandial increase of plasma arabinose and
xylan after ingestion of wheat-bran rich pasta
accompanied by a reduced rate of endogenous
glucose appearance rate compared to control
wheat bread.60 The authors of the latter study
propose that the increased availability of arabinox-
ylans may have increased luminal viscosity and
thereby may interfere with small intestinal glucose
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breakdown and absorption. Further, arabinose
itself has been shown to partly inhibit sucrase
and maltase activity in in vitro and in rodent
models,61-63 which potentially may attenuate
breakdown of glucose and thus early glucose-
dependent GLP-1 stimulation as observed in our
study. While AXOS intervention tended to
increase postprandial fat oxidation, there was no
effect of AXOS on other metabolic outcomes
including energy expenditure, glucose, and insulin,
or lipids or adipocyte functioning nor on gut per-
meability, plasma LBP, fecal calprotectin or other
systemic inflammatory markers.
A strength of this study was the thorough phe-
notypical characterization of participants regard-
ing the subjective and quantitative assessment of
gastrointestinal parameters and metabolic profile,
as well as the controlled randomized design.
A limitation of this study is that the inclusion of
healthy participants may have left less room for
improvement in metabolic health parameters com-
pared to metabolically compromised individuals
with obesity or type 2 diabetes. To summarize, 12-
week of AXOS intervention strongly increases
Bifidobacterium, reduces microbiota diversity and
softens stool consistency without changes in
WGTT and metabolic health. Overall microbiota
accurately classifies responders with decreased
WGTT indicating that changes in transit were
associated with gut microbiota composition inde-
pendent of Bifidobacterium. Hereby, we substanti-
ate the current notion that there is a complex
bidirectional interaction between the gut micro-
biota and GI transit and that prebiotic stimulation
of Bifidobacterium was not effective in improving
GI transit in this study population. Further studies
are warranted to disentangle the connections
between the gut microbiota and GI functioning
and whether these play a role in metabolic health.
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